Tafasitamab plus metronomic vinorelbine significantly inhibit phosphorylation of GSK3α/β, mTOR, p70S6K, RPS6 and TSC2 proteins in DLBCL cells. The gene discussed is GSK3A; the disease is diffuse large B-cell lymphoma.